SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 36.92 |
| Enterprise Value ($M) | 11.60 |
| Book Value ($M) | 70.82 |
| Book Value / Share | 1.71 |
| Price / Book | 0.52 |
| NCAV ($M) | 70.04 |
| NCAV / Share | 1.69 |
| Price / NCAV | 0.53 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.94 |
| Return on Assets (ROA) | -0.58 |
| Return on Equity (ROE) | -0.63 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.55 |
| Current Ratio | 9.55 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 78.23 |
| Assets | 79.01 |
| Liabilities | 8.19 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fmr Llc | 5.58 | -8.68 | |
| 13G | Johnson & Johnson | 8.80 | ||
| 13G/A | Canaan XI L.P. | 4.97 | -0.07 | |
| 13G/A | Viking Global Investors Lp | 11.10 | 0.00 | |
| 13D/A | Pivotal bioVenture Partners Fund I, L.P. | 6.40 | 5.87 | |
| 13G/A | Novo Holdings A/S | 4.70 | -23.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 15,323 | 40,439 | 37.89 | |
| 6,896 | 38,487 | 17.92 | |
| 9,190 | 39,506 | 23.26 | |
| 9,154 | 95,891 | 9.55 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RGNX – REGENXBIO Inc. | RIGL – Rigel Pharmaceuticals, Inc. |
| RLMD – Relmada Therapeutics, Inc. | ROIV – Roivant Sciences Ltd. |
| RPRX – Royalty Pharma plc |
Financial data and stock pages provided by
Fintel.io